{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:57:15Z","timestamp":1782554235725,"version":"3.54.5"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>In the last 40 years, a significant increase in the incidence of lung infections by Aspergillus has been reported. The scarcity of studies that describe the costs of aspergillosis indicates that the economic impact of aspergillosis in the hospital environment is greater than that of other fungal infections. The objective of the study was to evaluate the direct healthcare costs associated with aspergillosis in the Spanish National Health System from 1997 to 2021. A retrospective nationwide longitudinal descriptive study was designed to review hospital records from the Minimum Basic Data Set of patients admitted to hospitals of the National Health System from 1997 to 2021, with a diagnosis of aspergillosis. A total of 44,586 patients were admitted for aspergillosis in the Spanish National Health System. There was a progressive increase in the average annual cost from 1997 to 2012, which reached a maximum peak, EUR 1,395,154.21 (\u00b12,155,192.87). It decreased between 2014 and 2019, but increased again in 2020 and 2021, EUR 28,675.79 (\u00b130,384.12). The Pearson correlation coefficient revealed a weak negative correlation between age and hospital costs and a moderate positive correlation between average length of stay and hospital costs. Our data show that the economic impact of hospitalizations for aspergillosis is significant and increasing at a rate proportionally higher than that of other prevalent diseases. Costs related to Aspergillus infection are associated mainly with respiratory diseases. The results of this economic evaluation may be useful for health authorities to develop a future economic strategy for managing this fungal infection.<\/jats:p>","DOI":"10.3390\/jof10110733","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:07:04Z","timestamp":1729674424000},"page":"733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare Costs of Hospitalizations Due to Aspergillosis and 25-Year Trends in Spain, 1997\u20132021"],"prefix":"10.3390","volume":"10","author":[{"given":"Mar\u00eda","family":"Rinc\u00f3n Villar","sequence":"first","affiliation":[{"name":"Servicio de Medicina Interna, Complejo Asistencial Universitario de Palencia (CAUPA), Av. Donantes de Sangre, 34005 Palencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1829-5858","authenticated-orcid":false,"given":"Montserrat","family":"Alonso-Sard\u00f3n","sequence":"additional","affiliation":[{"name":"\u00c1rea de Medicina Preventiva y Salud P\u00fablica, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n en Enfermedades Tropicales (CIETUS), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Alvarez-Artero","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Complejo Asistencial Universitario de Palencia (CAUPA), Av. Donantes de Sangre, 34005 Palencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodr\u00edguez Alonso","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Unidad de Infecciosas, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n en Enfermedades Tropicales (CIETUS), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-4056","authenticated-orcid":false,"given":"Amparo","family":"L\u00f3pez-Bern\u00fas","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Secci\u00f3n de Enfermedades Infecciosas, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n en Enfermedades Tropicales (CIETUS), Universidad de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Romero-Alegr\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Unidad de Infecciosas, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n en Enfermedades Tropicales (CIETUS), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pardo-Lled\u00edas","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Marqu\u00e9s de Valdecilla, IDIVAL (Instituto de Investigaci\u00f3n Valdecilla), Universidad de Cantabria, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-1256","authenticated-orcid":false,"given":"Moncef","family":"Belhassen-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Secci\u00f3n de Enfermedades Infecciosas, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n en Enfermedades Tropicales (CIETUS), Universidad de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Latg\u00e9, J.P., and Chamilos, G. (2019). Aspergillus fumigatus and Aspergillosis in 2019. Clin. Microbiol. Rev., 33.","DOI":"10.1128\/CMR.00140-18"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/myc.13239","article-title":"Epidemiology of aspergillosis in hospitalised Spanish patients\u2014A 21-year retrospective study","volume":"64","author":"Carbonell","year":"2021","journal-title":"Mycoses"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2014","journal-title":"Thorax"},{"key":"ref_4","first-page":"56","article-title":"Invasive pulmonary aspergillosis in non-neutropenic patients. Rev. Espan\u0303ola Quimioter","volume":"29","author":"Tejeda","year":"2016","journal-title":"Publicacio\u0301n Of. La Soc. Espan\u0303ola Quimioter."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.riam.2014.07.004","article-title":"Aspergilosis pulmonar invasiva en el enfermo con enfermedad pulmonar obstructiva cr\u00f3nica","volume":"31","author":"Mensa","year":"2014","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.riam.2018.07.001","article-title":"Aspergilosis invasiva en el paciente cr\u00edtico","volume":"35","year":"2018","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4067\/S0716-10182019000600732","article-title":"Epidemiologa de la enfermedad f\u00fangica invasora por hongos filamentosos en el per\u00edodo 2005 a 2015, en un hospital universitario en Santiago, Chile","volume":"36","author":"Valenzuela","year":"2019","journal-title":"Rev. Chil Infectologa"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R., and Denning, D. (2017). Global and Multi-National Prevalence of Fungal Diseases\u2014Estimate Precision. J. Fungi, 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes","volume":"19","author":"Taccone","year":"2015","journal-title":"Crit. Care"},{"key":"ref_10","first-page":"302","article-title":"Estudio de costo del tratamiento de la aspergilosis invasora en pacientes oncolgicos peditricos: Santiago","volume":"27","author":"Moreno","year":"2010","journal-title":"Chile. Rev. Chil. Infectologa"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1130-1406(09)70016-6","article-title":"Farmacoeconom\u00eda del tratamiento de las candidiasis invasoras","volume":"26","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1130-6343(05)73629-1","article-title":"Evaluaci\u00f3n econ\u00f3mica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva","volume":"29","author":"Cerrato","year":"2005","journal-title":"Farm. Hosp."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.jval.2020.08.885","article-title":"PIN44 Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis: A Canadian Cost-Utility Analysis","volume":"23","author":"Beauchemin","year":"2020","journal-title":"Value Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Floros, L., Kuessner, D., Posthumus, J., Bagshaw, E., and Sj\u00f6lin, J. (2019). Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3683-2"},{"key":"ref_16","unstructured":"Portal Estad\u00edstico del SNS (2022, December 16). Ministerio de Sanidad, Servicios Sociales e Igualdad [Sede Web]. Available online: https:\/\/www.sanidad.gob.es."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Garc\u00eda, P., Alonso-Sard\u00f3n, M., Rodr\u00edguez-Alonso, B., Almeida, H., Romero-Alegr\u00eda, \u00c1., Vega-Rodr\u00edguez, V.J., L\u00f3pez-Bern\u00fas, A., Mu\u00f1oz-Bellido, J.L., Muro, A., and Pardo-Lled\u00edas, J. (2022). How Has the Aspergillosis Case Fatality Rate Changed over the Last Two Decades in Spain?. J. Fungi, 8.","DOI":"10.3390\/jof8060576"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0213-005X(17)30035-6","article-title":"Principales variables que determinan el coste econ\u00f3mico en el tratamiento de una infecci\u00f3n","volume":"35","author":"Grau","year":"2017","journal-title":"Enfermedades Infecc. Microbiol. Cl\u00edn."},{"key":"ref_19","first-page":"97","article-title":"Crisis econ\u00f3mica y patolog\u00eda infecciosa","volume":"28","year":"2014","journal-title":"Informe SESPAS 2014. Gac. Sanit."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eimc.2012.08.003","article-title":"Infecci\u00f3n f\u00fangica invasora en los pacientes hematol\u00f3gicos","volume":"30","author":"Llamas","year":"2012","journal-title":"Enfermedades Infecc. Microbiol. Cl\u00edn."},{"key":"ref_21","first-page":"16","article-title":"Gripe estacional en Espa\u00f1a: Carga cl\u00ednica y econ\u00f3mica y programas de vacunaci\u00f3n","volume":"153","author":"Platero","year":"2019","journal-title":"Med. Cl\u00edn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden Killers: Human Fungal Infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01229-21","DOI":"10.1128\/JCM.01229-21","article-title":"Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients","volume":"59","author":"Alanio","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.20430\/ete.v89i355.1307","article-title":"Consecuencias de la covid-19 en la econom\u00eda y las finanzas p\u00fablicas en M\u00e9xico: M\u00e1s all\u00e1 de la pandemia","volume":"89","author":"Morales","year":"2022","journal-title":"El Trimest. Econ."},{"key":"ref_26","first-page":"e1","article-title":"Assessment of Three Risk Adjustment Systems as Predictors of the Consumption of Medicines and Medical Supplies at Polyvalent Hospitalization Units","volume":"90","author":"Flores","year":"2016","journal-title":"Spain Rev. Espa\u00f1ola Salud Publica"},{"key":"ref_27","first-page":"12","article-title":"Lifting the weight of a diagnosis-related groups family change: A comparison between refined and non-refined DRG systems for top-down cost accounting and efficiency indicators","volume":"44","author":"Zlotnik","year":"2015","journal-title":"Health Inf. Manag. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5117\/mab.91.24045","article-title":"Performance differences between the episode-based DBC and diagnosis-related DRG case mix systems","volume":"91","author":"Groot","year":"2017","journal-title":"Maandbl. Voor Acc. Bedrijfsecon."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10198-022-01444-y","article-title":"Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database","volume":"23","author":"Epstein","year":"2022","journal-title":"Eur. J. Health Econ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13561-024-00522-6","article-title":"Retrospective analysis of hospitalization costs using two payment systems: The diagnosis related groups (DRG) and the Queralt system, a newly developed case-mix tool for hospitalized patients","volume":"14","author":"Folguera","year":"2024","journal-title":"Health Econ. Rev."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/11\/733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:18:48Z","timestamp":1760113128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/11\/733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jof10110733"],"URL":"https:\/\/doi.org\/10.3390\/jof10110733","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}